178 related articles for article (PubMed ID: 23550025)
1. Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia.
Fetterly GJ; Aras U; Lal D; Murphy M; Meholick PD; Wang ES
AAPS J; 2013 Jul; 15(3):662-73. PubMed ID: 23550025
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models.
Lal D; Park JA; Demock K; Marinaro J; Perez AM; Lin MH; Tian L; Mashtare TJ; Murphy M; Prey J; Wetzler M; Fetterly GJ; Wang ES
Mol Cancer Ther; 2010 Oct; 9(10):2737-51. PubMed ID: 20924124
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Thai HT; Veyrat-Follet C; Mentré F; Comets E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
Sanz-Garcia E; SaurĂ T; Tabernero J; Macarulla T
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report.
Glade Bender J; Blaney SM; Borinstein S; Reid JM; Baruchel S; Ahern C; Ingle AM; Yamashiro DJ; Chen A; Weigel B; Adamson PC; Park JR
Clin Cancer Res; 2012 Sep; 18(18):5081-9. PubMed ID: 22791883
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
Lopes de Menezes DE; Mayer LD
Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy.
Shao Y; Luo W; Guo Q; Li X; Zhang Q; Li J
Drug Des Devel Ther; 2019; 13():2043-2055. PubMed ID: 31388296
[No Abstract] [Full Text] [Related]
8. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA
Oncology; 2016; 90(1):10-20. PubMed ID: 26492090
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors.
Sharma T; Dhingra R; Singh S; Sharma S; Tomar P; Malhotra M; Bhardwaj TR
Mini Rev Med Chem; 2013 Apr; 13(4):530-40. PubMed ID: 23317499
[TBL] [Abstract][Full Text] [Related]
10. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
Yang C; Boyson CA; Di Liberto M; Huang X; Hannah J; Dorn DC; Moore MA; Chen-Kiang S; Zhou P
Cancer Res; 2015 May; 75(9):1838-45. PubMed ID: 25744718
[TBL] [Abstract][Full Text] [Related]
11. Enhanced tumor delivery and antitumor response of doxorubicin-loaded albumin nanoparticles formulated based on a Schiff base.
Li F; Zheng C; Xin J; Chen F; Ling H; Sun L; Webster TJ; Ming X; Liu J
Int J Nanomedicine; 2016; 11():3875-90. PubMed ID: 27574421
[TBL] [Abstract][Full Text] [Related]
12. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer.
Perkins SL; Cole SW
Ann Pharmacother; 2014 Jan; 48(1):93-8. PubMed ID: 24259608
[TBL] [Abstract][Full Text] [Related]
13. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST
Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model.
Pan XQ; Wang H; Lee RJ
Pharm Res; 2003 Mar; 20(3):417-22. PubMed ID: 12669962
[TBL] [Abstract][Full Text] [Related]
16. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.
Tschulakow A; Christner S; Julien S; Ludinsky M; van der Giet M; Schraermeyer U
PLoS One; 2014; 9(11):e113701. PubMed ID: 25415380
[TBL] [Abstract][Full Text] [Related]
17. Preclinical PK/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer.
Yao QY; Li J; Chen R; Yao Y; Xue JS; Chen WJ; Lu W; Zhou TY
Acta Pharmacol Sin; 2019 Dec; 40(12):1596-1602. PubMed ID: 31165782
[TBL] [Abstract][Full Text] [Related]
18. The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells.
Tu HJ; Lin YJ; Chao MW; Sung TY; Wu YW; Chen YY; Lin MH; Liou JP; Pan SL; Yang CR
Clin Epigenetics; 2018 Dec; 10(1):162. PubMed ID: 30594243
[TBL] [Abstract][Full Text] [Related]
19. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]